share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 4:持股变动声明-高管 Shutterly Andrew
美股SEC公告 ·  08/01 17:51
Moomoo AI 已提取核心信息
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.
Altimmune公司临时代码致富金融执行首席财务官Andrew Shutterly于2024年7月31日购买了1,259股普通股。交易价格为每股5.41美元,总投资约6,811.99美元。此次收购后,Shutterly在该公司的直接持股数量增加至11,372股普通股。该交易反映出直接持有权益,并根据交易代码“A”报告为授权、奖励或其他收购。
Altimmune公司临时代码致富金融执行首席财务官Andrew Shutterly于2024年7月31日购买了1,259股普通股。交易价格为每股5.41美元,总投资约6,811.99美元。此次收购后,Shutterly在该公司的直接持股数量增加至11,372股普通股。该交易反映出直接持有权益,并根据交易代码“A”报告为授权、奖励或其他收购。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息